Cantargia reports encouraging new CAN10 toxicology results and schedules phase I trial for 2023
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new encouraging results from non-GLP toxicology and pharmacokinetic studies for its anti-inflammatory IL1RAP-binding antibody CAN10. Results show no toxicologically relevant changes using a new subcutaneous formulation, with high bioavailability and desirable pharmacological half-life. Further studies using intravenous administration show good safety by repeated dosing at 50 mg/kg. The GLP toxicology studies for CAN10 are scheduled to start Q2 2022, with timelines slightly adjusted to fit with global capacity during the COVID